Inhibition of vein graft stenosis with a c-jun targeting DNAzyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)

Background/objectives Coronary artery bypass grafting (CABG) is among the most commonly performed heart surgical procedures. Saphenous vein graft failure due to stenosis impedes the longer-term success of CABG. A key cellular event in the process of vein graft stenosis is smooth muscle cell hyperpl...

Full description

Bibliographic Details
Main Authors: Li, Yue, Bhindi, Ravinay, Deng, Zhou J., Morton, Stephen Winford, Khachigian, Levon M., Hammond, Paula T
Other Authors: Massachusetts Institute of Technology. Department of Chemical Engineering
Format: Article
Language:en_US
Published: 2016
Online Access:http://hdl.handle.net/1721.1/101177
_version_ 1826217951672401920
author Li, Yue
Bhindi, Ravinay
Deng, Zhou J.
Morton, Stephen Winford
Khachigian, Levon M.
Hammond, Paula T
author2 Massachusetts Institute of Technology. Department of Chemical Engineering
author_facet Massachusetts Institute of Technology. Department of Chemical Engineering
Li, Yue
Bhindi, Ravinay
Deng, Zhou J.
Morton, Stephen Winford
Khachigian, Levon M.
Hammond, Paula T
author_sort Li, Yue
collection MIT
description Background/objectives Coronary artery bypass grafting (CABG) is among the most commonly performed heart surgical procedures. Saphenous vein graft failure due to stenosis impedes the longer-term success of CABG. A key cellular event in the process of vein graft stenosis is smooth muscle cell hyperplasia. In this study, we evaluated the effect of a DNAzyme (Dz13) targeting the transcription factor c-Jun in a rabbit model of vein graft stenosis in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). Dz13 in DOTAP/DOPE has undergone preclinical toxicological testing, and a Phase I clinical trial we recently conducted in basal cell carcinoma cancer patients demonstrates that it is safe and well tolerated after local administration. Methods Effects of Dz13 in a formulation containing DOTAP/DOPE on smooth muscle cell (SMC) growth and c-Jun expression were assessed. Dz13 transfection was determined by cellular uptake of carboxyfluorescein-labeled Dz13. Autologous jugular vein to carotid artery transplantation was performed in New Zealand White rabbits to investigate the effect of the Dz13 in DOTAP/DOPE formulation on intimal hyperplasia. Results Dz13/DOTAP/DOPE reduced SMC proliferation and c-Jun protein expression in vitro compared with an impotent form of Dz13 bearing a point mutation in its catalytic domain (Dz13.G > C). The Dz13(500 μg)/DOTAP/DOPE formed lipoplexes that were colloidally stable for up to 1 h on ice (0 °C) and 30 min at 37 °C, allowing sufficient uptake by the veins. Dz13 (500 μg) inhibited neointima formation 28 d after end-to-side transplantation. Conclusions This formulation applied to veins prior to transplantation may potentially be useful in efforts to reduce graft failure.
first_indexed 2024-09-23T17:11:39Z
format Article
id mit-1721.1/101177
institution Massachusetts Institute of Technology
language en_US
last_indexed 2024-09-23T17:11:39Z
publishDate 2016
record_format dspace
spelling mit-1721.1/1011772022-10-03T11:04:12Z Inhibition of vein graft stenosis with a c-jun targeting DNAzyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) Li, Yue Bhindi, Ravinay Deng, Zhou J. Morton, Stephen Winford Khachigian, Levon M. Hammond, Paula T Massachusetts Institute of Technology. Department of Chemical Engineering Koch Institute for Integrative Cancer Research at MIT Deng, Zhou J. Morton, Stephen Winford Hammond, Paula T. Background/objectives Coronary artery bypass grafting (CABG) is among the most commonly performed heart surgical procedures. Saphenous vein graft failure due to stenosis impedes the longer-term success of CABG. A key cellular event in the process of vein graft stenosis is smooth muscle cell hyperplasia. In this study, we evaluated the effect of a DNAzyme (Dz13) targeting the transcription factor c-Jun in a rabbit model of vein graft stenosis in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). Dz13 in DOTAP/DOPE has undergone preclinical toxicological testing, and a Phase I clinical trial we recently conducted in basal cell carcinoma cancer patients demonstrates that it is safe and well tolerated after local administration. Methods Effects of Dz13 in a formulation containing DOTAP/DOPE on smooth muscle cell (SMC) growth and c-Jun expression were assessed. Dz13 transfection was determined by cellular uptake of carboxyfluorescein-labeled Dz13. Autologous jugular vein to carotid artery transplantation was performed in New Zealand White rabbits to investigate the effect of the Dz13 in DOTAP/DOPE formulation on intimal hyperplasia. Results Dz13/DOTAP/DOPE reduced SMC proliferation and c-Jun protein expression in vitro compared with an impotent form of Dz13 bearing a point mutation in its catalytic domain (Dz13.G > C). The Dz13(500 μg)/DOTAP/DOPE formed lipoplexes that were colloidally stable for up to 1 h on ice (0 °C) and 30 min at 37 °C, allowing sufficient uptake by the veins. Dz13 (500 μg) inhibited neointima formation 28 d after end-to-side transplantation. Conclusions This formulation applied to veins prior to transplantation may potentially be useful in efforts to reduce graft failure. National Health and Medical Research Council (Australia) National Heart Foundation (Australia) Heart Research Australia 2016-02-12T18:58:46Z 2016-02-12T18:58:46Z 2013-07 2013-05 Article http://purl.org/eprint/type/JournalArticle 01675273 http://hdl.handle.net/1721.1/101177 Li, Yue, Ravinay Bhindi, Zhou J. Deng, Stephen W. Morton, Paula T. Hammond, and Levon M. Khachigian. “Inhibition of Vein Graft Stenosis with a c-Jun Targeting DNAzyme in a Cationic Liposomal Formulation Containing 1,2-Dioleoyl-3-Trimethylammonium Propane (DOTAP)/1,2-Dioleoyl-Sn-Glycero-3-Phosphoethanolamine (DOPE).” International Journal of Cardiology 168, no. 4 (October 2013): 3659–3664. en_US http://dx.doi.org/10.1016/j.ijcard.2013.05.092 International Journal of Cardiology Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf PMC
spellingShingle Li, Yue
Bhindi, Ravinay
Deng, Zhou J.
Morton, Stephen Winford
Khachigian, Levon M.
Hammond, Paula T
Inhibition of vein graft stenosis with a c-jun targeting DNAzyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)
title Inhibition of vein graft stenosis with a c-jun targeting DNAzyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)
title_full Inhibition of vein graft stenosis with a c-jun targeting DNAzyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)
title_fullStr Inhibition of vein graft stenosis with a c-jun targeting DNAzyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)
title_full_unstemmed Inhibition of vein graft stenosis with a c-jun targeting DNAzyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)
title_short Inhibition of vein graft stenosis with a c-jun targeting DNAzyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)
title_sort inhibition of vein graft stenosis with a c jun targeting dnazyme in a cationic liposomal formulation containing 1 2 dioleoyl 3 trimethylammonium propane dotap 1 2 dioleoyl sn glycero 3 phosphoethanolamine dope
url http://hdl.handle.net/1721.1/101177
work_keys_str_mv AT liyue inhibitionofveingraftstenosiswithacjuntargetingdnazymeinacationicliposomalformulationcontaining12dioleoyl3trimethylammoniumpropanedotap12dioleoylsnglycero3phosphoethanolaminedope
AT bhindiravinay inhibitionofveingraftstenosiswithacjuntargetingdnazymeinacationicliposomalformulationcontaining12dioleoyl3trimethylammoniumpropanedotap12dioleoylsnglycero3phosphoethanolaminedope
AT dengzhouj inhibitionofveingraftstenosiswithacjuntargetingdnazymeinacationicliposomalformulationcontaining12dioleoyl3trimethylammoniumpropanedotap12dioleoylsnglycero3phosphoethanolaminedope
AT mortonstephenwinford inhibitionofveingraftstenosiswithacjuntargetingdnazymeinacationicliposomalformulationcontaining12dioleoyl3trimethylammoniumpropanedotap12dioleoylsnglycero3phosphoethanolaminedope
AT khachigianlevonm inhibitionofveingraftstenosiswithacjuntargetingdnazymeinacationicliposomalformulationcontaining12dioleoyl3trimethylammoniumpropanedotap12dioleoylsnglycero3phosphoethanolaminedope
AT hammondpaulat inhibitionofveingraftstenosiswithacjuntargetingdnazymeinacationicliposomalformulationcontaining12dioleoyl3trimethylammoniumpropanedotap12dioleoylsnglycero3phosphoethanolaminedope